Communiqués Atai Life Sciences N.V.

Actions

ATAI

NL0015000DX5

Temps réel estimé Cboe BZX Autres places de cotation 21:04:13 12/06/2024			Varia. 5j.	Varia. 1 janv.
1,335 ^USD	+1,14 %		-5,67 %	-5,67 %

23/05	Atai Life Sciences N.V. annonce des changements au sein de son conseil d'administration et de son conseil de surveillance	CI
20/05	Un initié d'Atai Life Sciences a vendu des actions d'une valeur de 290 502 $, selon un récent dépôt auprès de la SEC	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Atai Life Sciences N : Company Presentation June 2024	05/06	PU
Atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference	03/06	AQ
Atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference	31/05	GL
Atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors	23/05	GL
Atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors	23/05	AQ
Atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates	15/05	GL
Atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates	15/05	AQ
Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression	25/04	AQ
Atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression	24/04	GL
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology	17/04	GL
Momentum Stocks Alert: DYAI, KAVL, VTAK, NKLA, ATAI Demonstrate Financial Growth and Strategic Advancements	08/04	AQ
Atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 in Treatment Resistant Depression	28/03	AQ
Atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights	28/03	GL
Atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights	28/03	AQ
Atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression	27/03	GL
Atai Life Sciences advances VLS-01 for treatment-resistant depression	12/03	AQ
Atai Life Sciences N : Company Presentation March 2024	04/03	PU
Atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01	04/03	GL
Atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01	04/03	AQ
Atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference	28/02	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Atai Life Sciences N.V.

Actions

ATAI

NL0015000DX5

Communiqués

Filtres